A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients

Inclusion Criteria: * Patients require a diagnosis of post-traumatic peripheral neuropathic pain (NeP), including post-surgical NeP and NeP due to peripheral nerve injury, which has lasted at least 3 months following the traumatic event. * Patients during the screening week must have completed ≥ 4 daily pain scores and have an average daily pain score ≥ 4. * Female patients of childbearing potential must have a negative urine pregnancy test at Screening and be practicing an acceptable form of contraception. Exclusion Criteria: * Patients with neuropathic pain (NeP) that is not due to trauma; e.g. patients with trigeminal neuralgia, central pain, complex region pain syndrome type I, phantom limb pain, radiculopathy, painful diabetic neuropathy or post-herpetic neuralgia or patients with any other co-existing pain which cannot be differentiate from NeP of peripheral origin. * Patients who have previously failed to respond to pregabalin at a total daily dose of equal to or greater than 300 mg or are intolerant to those doses. * Patients who have previously failed to respond to gabapentin at a total daily dose of equal to or greater than 1800 mg. * Patients with any type or history of malignancy, except either where there has been no ongoing treatment for at least 6 months or all basal cell carcinomas; all patients with a history of brain or spinal tumors will be excluded. * Patients who currently have ongoing litigation related to any injury affecting their pain symptomatology.